Spark Therapeutics — Investor Presentation (March 2015)
29 slides from Spark Therapeutics's investor presentation, Mar 4, 2015
Slide 1: Corporate Presentation
Exhibit 99.1 Corporate Presentation
Slide 2: Forward-looking statements
Forward-looking statements This presentation includes ‘‘forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation
Slide 3: Spark: An integrated gene therapy company developing one-time, life-altering treatments
Spark: An integrated gene therapy company developing one-time, life-altering treatments for debilitating genetic disorders Founded on know-how accumulated over 20 years at CHOP including manufacturing platform applied safely across >150 administrations Promising clinical outcomes in rare blinding co
Slide 4: Transforming lives by restoring functional vision through a one-time administration of SPK-RPE65
Transforming lives by restoring functional vision through a one-time st administration of SPK-RPE65 (1 eye, subject CH-09) Navigation abilities in patients with IRDs Navigation after a single injection of SPK- can be limited (uninjected eye) RPE65 (injected eye) Source: Maguire, et al., Lancet. 2009
Slide 5: SPK-RPE65 demonstrated evidence of life-altering improvement in light sensitivity
SPK-RPE65 demonstrated evidence of life-altering improvement in nd light sensitivity (2 eye, all Phase 3-eligible subjects) Lux level Approximately equivalent to: 1 Moonless summer night or indoor nightlight 4 Outdoor parking lot at night or Christmas tree lights 10 An hour following sunset in a cit
Slide 6: Broad pipeline of AAV candidates including strategic collaborations with Pfizer and Genable
Broad pipeline of AAV (a well-studied vector) candidates including strategic collaborations with Pfizer and Genable Technologies Program Preclinical IND-enabling Phase 1/2 Phase 3 Status Commercial rights Inherited retinal dystrophies SPK-RPE65: Phase 3 enrolled with Worldwide rights RPE65-mediated
Slide 7: Leadership team of gene therapy pioneers, experienced life sciences entrepreneurs and commercial executives
Leadership team of gene therapy pioneers, experienced life sciences entrepreneurs and commercial executives Gene Therapy Pioneers Life Sciences Entrepreneurs and Executives Katherine A. High, MD – President and CSO Jeffrey D. Marrazzo – CEO (Spark co-founder and (founding director of CHOP gene thera
Slide 8: Platform to treat blindness due to IRDs led by Phase 3 program, SPK-RPE65
Platform to treat blindness due to IRDs led by Phase 3 program, SPK-RPE65
Slide 9: Platform for treating IRDs creates substantial pipeline potential
Platform for treating IRDs creates substantial pipeline potential SPK-RPE65 in fully enrolled pivotal Phase 3 clinical trial FDA breakthrough therapy with evidence of life-altering, long- lasting effects and long-term safety in Phase 1 trials Phase 3 data expected in second half of 2015 ~3,500 patie
Slide 10: IRDs mediated by autosomal recessive RPE65 mutations
IRDs mediated by autosomal recessive RPE65 mutations RPE65 encodes a protein that helps convert light entering the eye into electrical signals that are transmitted to the brain Disease characterized by many visual impairments: night blindness, diminished light sensitivity, reduced visual fields, nys
Slide 11: SPK-RPE65 adds a normal, functional copy of the gene to overcome effects of defective gene
SPK-RPE65 adds a normal, functional copy of the gene to overcome effects of defective gene Note: Video used with permission from Foundation Fighting Blindness: https://www.blindness.org or 800.683.5555. Producing healthy RPE65 protein believed to re-establish the visual cycle and restore functional
Slide 12: SPK-RPE65: Phase 1 clinical trials summary
SPK-RPE65: Phase 1 clinical trials summary Phase 1 dose escalating (101 Trial) Phase 1 high dose, contralateral eye (102 Trial) Open label, dose escalating trial of 3 Open label, high dose injection to the cohorts – worse (or non-preferred) eye only contralateral (better, or preferred) eye of 11 in
Slide 13: SPK-RPE65: Measuring functional vision through a validated mobility test
SPK-RPE65: Measuring functional vision through a validated mobility test Lux levels 1 Mobility course layout (1 of 12) Moonless summer night or indoor nightlight 4 Outdoor parking lot at night or Christmas tree lights 10 An hour following sunset in a city setting or a bus stop at night 50 Outdoor tr
Slide 14: SPK-RPE65: Mobility test change score results from 102 Trial
SPK-RPE65: Mobility test change score results from 102 Trial Lux level Approximately equivalent to: 1 Moonless summer night or indoor nightlight 4 Outdoor parking lot at night or Christmas tree lights 10 An hour following sunset in a city setting or a bus stop at night 50 Outdoor train station at ni
Slide 15: SPK-RPE65: Frequent, collaborative dialogue with regulatory agencies and Breakthrough Therapy Designation
SPK-RPE65: Frequent, collaborative dialogue with regulatory agencies and Breakthrough Therapy Designation granted by FDA Agreement with FDA to reduce minimum age, shorten inter-subject interval and conduct bilateral, non- 2008 simultaneous administration Orphan Product Designation granted by FDA for
Slide 16: SPK-RPE65: Fully enrolled Phase 3 trial on track with data expected in 2H15
SPK-RPE65: Fully enrolled Phase 3 trial on track with data expected in 2H15 Study fully enrolled Data expected in 2H15 First 2nd Endpoint Intervention injection injection Baseline testing group reached at 1 ( 90 days (12 6 (n = 19) of baseline) days) year Randomization (2:1 intervention Eligibility
Slide 17: SPK-RPE65: Market opportunity and commercialization model
SPK-RPE65: Market opportunity and commercialization model RPE65 mutations associated with subtypes of Leber’s Estimated Prevalence 1 congenital amaurosis (LCA), retinitis pigmentosa (RP) of RPE65-mediated ~6% to 11% of LCA patients (LCA2) IRDs 6,000 ~1% to 3% of RP patients (RP20) 5,000 An estimated
Slide 18: SPK-RPE65 creates a platform for addressing additional IRDs
SPK-RPE65 creates a platform for addressing additional IRDs More than 220 genes have been identified to cause IRDs, each of which could leverage aspects of SPK-RPE65: Comparable vector, delivery and target may reduce technical risks and ability to cross- reference safety data may reduce development
Slide 19: SPK-CHM: Leveraging the experience with SPK-RPE65 to treat choroideremia
SPK-CHM: Leveraging the experience with SPK-RPE65 to treat choroideremia Vector Expression Route of Target cells in Manufacturing Commercialization Gene capsid cassette administration retina process model Product candidate SPK-RPE65 RPE65 AAV2 CBA Sub-retinal RPE Scaled COE SPK-CHM CHM AAV2 eCBA Sub
Slide 20: SPK-CHM: Phase 1/2 trial underway
SPK-CHM: Phase 1/2 trial underway Preclinical studies Phase 1/2 clinical trial Demonstrated the ability of SPK-CHM to IND cleared for dose-escalating trial of up restore: to 10 subjects REP-1 protein production Trial site opened at CHOP and Penn Intracellular trafficking including same surgeon and c
Slide 21: Collaboration with Genable Technologies on RhoNova for the treatment of RHO-adRP
Collaboration with Genable Technologies on RhoNova for the treatment of RHO-adRP adds to pipeline opportunity Vector Expression Route of Target cells in Manufacturing Commercialization Gene capsid cassette administration retina process model Product candidate SPK-RPE65 RPE65 AAV2 CBA Sub-retinal RPE
Slide 22: Potential to address additional IRDs
Potential to address additional IRDs Expected % Estimated US patient Clinical Diagnosis addressed by current population 1 product candidates Choroideremia 4,500 100% Leber’s Congenital Amaurosis 4,000 6%–11% Leber’s Hereditary Optic Neuropathy 8,000 0% Retinitis Pigmentosa 70,000 1%–3%; 20% 2 Retino
Slide 23: Hematologic and neurodegenerative disease pipeline led by Pfizer SPK-FIX collaboration
Hematologic and neurodegenerative disease pipeline led by Pfizer SPK-FIX collaboration
Slide 24: Hemophilia B experience creates product and platform opportunity
Hemophilia B experience creates product and platform opportunity During the year following infusion in July 2013 with predecessor vector, Michael’s need for Factor IX was reduced from ~50 times a year to once, exemplifying the potential to target hematologic and other disorders with a liver-directed
Slide 25: Predecessor gene therapy candidate: Phase 1 results
Predecessor gene therapy candidate: Phase 1 results Predecessor candidate: IV administration of Factor IX gene using AAV8 vector Both doses were safe and directed therapeutic levels of expression Expression cassette transduces human liver and generated >10% Factor IX activity in one patient (for sev
Slide 26: SPK-FIX: Product design, status and Pfizer collaboration
SPK-FIX: Product design, status and Pfizer collaboration Next generation product design Global collaboration with Pfizer Proprietary, bio-engineered capsid to potentially $20 million upfront payment received in reduce immunogenicity and provide stronger IP December 2014 protection Up to $260 million
Slide 27: SPK-FIX program is a first example of a potential pipeline targeting rare hematologic disorders
SPK-FIX program is a first example of a potential pipeline targeting rare hematologic disorders and neurodegenerative diseases Program Preclinical IND-enabling Phase 1/2 Phase 3 Status Commercial rights Inherited retinal dystrophies SPK-RPE65: Phase 3 enrolled with Worldwide rights RPE65-mediated IR
Slide 28: Summary
Summary
Slide 29: Executing on Spark vision
Executing on Spark vision SPK-RPE65: Submit BLA in US if Phase 3 $185 million IPO data are positive Collaboration with SPK-CHM: Phase 1/2 SPK-RPE65: Execute Genable on RhoNova trial underway pre-launch plan $73 million Series B SPK-FIX: Initiate Phase 1/2 trial Acquired rights to IP and programs fro
Spark Therapeutics — Investor Presentation (March 2015) on 6ix